GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » 3-Year EPS without NRI Growth Rate

Suven Pharmaceuticals (BOM:543064) 3-Year EPS without NRI Growth Rate : 8.60% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Suven Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was ₹1.84.

During the past 12 months, Suven Pharmaceuticals's average EPS without NRI Growth Rate was 10.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Suven Pharmaceuticals was 54.60% per year. The lowest was 8.60% per year. And the median was 31.60% per year.


Competitive Comparison of Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Suven Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Suven Pharmaceuticals  (BOM:543064) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Suven Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Pharmaceuticals (BOM:543064) Business Description

Traded in Other Exchanges
Address
3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines